CO6400186A2 - Tabletas de acetato de ulipristal - Google Patents

Tabletas de acetato de ulipristal

Info

Publication number
CO6400186A2
CO6400186A2 CO11081262A CO11081262A CO6400186A2 CO 6400186 A2 CO6400186 A2 CO 6400186A2 CO 11081262 A CO11081262 A CO 11081262A CO 11081262 A CO11081262 A CO 11081262A CO 6400186 A2 CO6400186 A2 CO 6400186A2
Authority
CO
Colombia
Prior art keywords
weight
amount
ulipristal acetate
acetate tablets
tablets
Prior art date
Application number
CO11081262A
Other languages
English (en)
Inventor
Erin Gainer
Helene Guillard
Denis Gicquel
Marianne Henrion
Celine Gnakamene
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41621124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6400186(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of CO6400186A2 publication Critical patent/CO6400186A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una tableta farmacéutica para administración oral que comprende acetato de ulipristal junto con los siguientes excipientes: al menos un diluyente en una cantidad de 50 a 98.5% en peso, al menos un agente enlazante en una cantidad de 0 a 10% en peso, al menos un agente desintegrante en una cantidad de 0.5 a 10% en peso, y al menos un lubricante en una cantidad de 0 a 10% en peso.
CO11081262A 2008-12-08 2011-06-29 Tabletas de acetato de ulipristal CO6400186A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/329,865 US8512745B2 (en) 2008-12-08 2008-12-08 Ulipristal acetate tablets

Publications (1)

Publication Number Publication Date
CO6400186A2 true CO6400186A2 (es) 2012-03-15

Family

ID=41621124

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11081262A CO6400186A2 (es) 2008-12-08 2011-06-29 Tabletas de acetato de ulipristal

Country Status (28)

Country Link
US (5) US8512745B2 (es)
EP (2) EP3103445A1 (es)
JP (2) JP5784502B2 (es)
KR (1) KR101733533B1 (es)
CN (2) CN102245173A (es)
AU (1) AU2009326084B2 (es)
BR (1) BRPI0922796A2 (es)
CA (1) CA2745084C (es)
CO (1) CO6400186A2 (es)
CY (1) CY1118099T1 (es)
DK (1) DK2365800T3 (es)
ES (1) ES2596554T3 (es)
HK (1) HK1232134A1 (es)
HR (1) HRP20161262T1 (es)
HU (1) HUE030762T2 (es)
IL (1) IL213247A (es)
LT (1) LT2365800T (es)
MX (1) MX343358B (es)
NZ (1) NZ593498A (es)
PL (1) PL2365800T3 (es)
PT (1) PT2365800T (es)
RS (1) RS55209B1 (es)
RU (1) RU2492853C2 (es)
SI (1) SI2365800T1 (es)
SM (1) SMT201600372B (es)
UA (1) UA101863C2 (es)
WO (1) WO2010066749A2 (es)
ZA (1) ZA201104137B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2615475C3 (de) * 1976-04-09 1984-05-03 Philips Patentverwaltung Gmbh, 2000 Hamburg Sonnenkollektor mit einer Abdeckung aus evakuierten Rohren
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
CN102395373A (zh) 2009-04-14 2012-03-28 Hra医药实验室 按需避孕方法
EP2471537A1 (en) 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
CN102727457B (zh) * 2011-04-08 2014-05-28 华润紫竹药业有限公司 稳定的醋酸优力司特制剂
FR2987271B1 (fr) 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
ES2672727T3 (es) * 2012-05-25 2018-06-15 Laboratoire Hra Pharma Acetato de ulipristal para la prevención y el tratamiento de tumores de mama
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2999081B1 (fr) * 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
CN103006603B (zh) * 2013-01-11 2015-04-15 山东创新药物研发有限公司 醋酸乌利司他的固体分散体及固体制剂
CN103083326A (zh) * 2013-02-04 2013-05-08 四川尚锐生物医药有限公司 一种醋酸优力司特药物组合物
WO2014167510A2 (en) * 2013-04-10 2014-10-16 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
CN104865215A (zh) * 2015-05-16 2015-08-26 南京海纳医药科技有限公司 一种醋酸乌利司他片剂及其溶出度测定方法
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
CN107982230A (zh) * 2017-12-25 2018-05-04 郑州泰丰制药有限公司 一种醋酸乌利司他分散片及其制备方法
CN114137115B (zh) * 2021-11-26 2023-08-04 四川尚锐分析检测有限公司 一种采用lc-ms法检测血浆中醋酸优力司特及其代谢物的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5084277A (en) * 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US20060111577A1 (en) 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
WO2005087194A1 (en) 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
WO2007030153A2 (en) * 2005-04-28 2007-03-15 Wyeth Compositions containing micronized tanaproget
WO2006116596A2 (en) 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
US8475838B2 (en) 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
ES2814343T3 (es) 2006-10-24 2021-03-26 Allergan Pharmaceuticals Int Ltd Composiciones y métodos para suprimir las proliferaciones endometriales
RU2465907C2 (ru) 2006-12-20 2012-11-10 Тева Вимен'С Хелс, Инк. Распадающиеся в полости рта твердые дозированные формы, содержащие прогестин, и способы получения и применение указанных дозированных форм
MX2009006912A (es) 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
KR20090105944A (ko) 2007-01-17 2009-10-07 레프로스 쎄라피우틱스 아이엔씨. 11-(4-아미노페닐)-19-노르프레그나-4,9(10)-디엔-3,20-디온 유도체의 약학적으로 허용가능한 염
HUE029397T2 (en) 2007-04-20 2017-03-28 Preglem Sa Selective progesterone modulators for treating uterine bleeding
US20090117183A1 (en) 2007-11-05 2009-05-07 Sabine Fricke Oral contraceptive containing a gestagen and an estrogen combined with pharmaceutically acceptable auxiliary agents and/or excipients, but not containing lactose, and method of making same
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets

Also Published As

Publication number Publication date
UA101863C2 (uk) 2013-05-13
CN105267168A (zh) 2016-01-27
KR101733533B1 (ko) 2017-05-10
ZA201104137B (en) 2012-02-29
JP2012511041A (ja) 2012-05-17
EP2365800A2 (en) 2011-09-21
US8735380B2 (en) 2014-05-27
RU2011127989A (ru) 2013-01-20
MX343358B (es) 2016-11-03
WO2010066749A2 (en) 2010-06-17
EP2365800B1 (en) 2016-07-20
SI2365800T1 (sl) 2017-01-31
HUE030762T2 (en) 2017-05-29
BRPI0922796A2 (pt) 2017-07-11
SMT201600372B (it) 2017-01-10
AU2009326084B2 (en) 2014-06-05
NZ593498A (en) 2012-07-27
JP2015107994A (ja) 2015-06-11
US9844510B2 (en) 2017-12-19
HK1232134A1 (zh) 2018-01-05
PT2365800T (pt) 2016-10-25
US20100144692A1 (en) 2010-06-10
PL2365800T3 (pl) 2017-03-31
RU2492853C2 (ru) 2013-09-20
US8512745B2 (en) 2013-08-20
US20140228335A1 (en) 2014-08-14
MX2011006106A (es) 2011-06-24
EP3103445A1 (en) 2016-12-14
JP6151727B2 (ja) 2017-06-21
LT2365800T (lt) 2016-11-10
US20180064651A1 (en) 2018-03-08
AU2009326084A1 (en) 2011-07-07
JP5784502B2 (ja) 2015-09-24
DK2365800T3 (en) 2016-10-24
IL213247A (en) 2015-07-30
HRP20161262T1 (hr) 2016-12-16
US20120077790A1 (en) 2012-03-29
CY1118099T1 (el) 2017-06-28
KR20110097936A (ko) 2011-08-31
CA2745084A1 (en) 2010-06-17
RS55209B1 (sr) 2017-01-31
WO2010066749A3 (en) 2010-08-05
US20160287518A1 (en) 2016-10-06
IL213247A0 (en) 2011-07-31
CN102245173A (zh) 2011-11-16
ES2596554T3 (es) 2017-01-10
CA2745084C (en) 2014-11-18

Similar Documents

Publication Publication Date Title
CO6400186A2 (es) Tabletas de acetato de ulipristal
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
UY31867A (es) Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
MX2011002065A (es) Composicion farmaceutica a base de progesterona micronizada y sus usos.
GT201200348A (es) Composiciones farmacèuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona
BR112015017451A2 (pt) formulações farmacêuticas resistentes à violação
BR112015011430A2 (pt) composição para liberação imediata e prolongada
MX2012013021A (es) Formulaciones resistentes a alcohol.
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
EA201170512A1 (ru) Композиция для перорального введения
TN2015000135A1 (en) Modified release formulations for oprozomib
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
UY35235A (es) Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
MX370184B (es) Composición farmacéutica que comprende fingolimod.
EA201170843A1 (ru) Предварительно спрессованные быстро распадающиеся лекарственные формы соединений с низкой пероральной биодоступностью
BR112013000870A2 (pt) forma de dosagem farmacêutica oral em comprimidos
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
UA108865C2 (uk) Парентеральна фармацевтична композиція у вигляді суспензії уповільненого вивільнення, у низькій та наднизькій дозованій формі, у гормональній терапії при клімактеричному синдромі

Legal Events

Date Code Title Description
FC Application refused